Treatment of Opioid Use Disorder: Waiver Qualifying - New York- Monday, June 11, 2018
- Registration Closed
Monday, June 11, 2018|1:00 pm - 5:00 pm
Highland Family Medicine
Rooms HUFF A/B
777 S. Clinton Ave
Rochester, NY 14620
Cost: FREE
Meals will be provided
Attendees completing this program are eligible for free CME
After attending if you begin prescribing buprenorphine or if you engage the CASAC at your office you will be eligible for a $250 honorarium
Hosted by Highland Hospital, Department of Family Medicine
Welcome to the ASAM Treatment of Opioid Use Disorder Course online access. This course covers all medications and treatments for opioid use disorder, and provides the required education needed to obtain the waiver to prescribe buprenorphine. ASAM is an approved provider by CSAT/SAMHSA of DATA 2000 training.
This is an 8-hour blended course combining 4 hours of online learning followed by 4 hours of live learning. The live portion of the course builds off the content delivered in the online portion. Course faculty are expecting you to come to the live course with the online portion completed.
Included with this program, individual clinician-to-clinician consultation will be available to aid you in establishing a MAT-prescribing program at your practice. In addition, a Certified Alcohol and Substance Abuse Counselor (CASAC) will be available to your staff for instruction and support on overcoming the challenges associated with a MAT prescribing program and gaining comfort in the treatment of addiction as a chronic disease.
Getting started: To begin the online portion of the course, please log in to your right and locate the box that says Module 1. If you do not know your password, or you have forgotten it, select Forgot Password and you will be emailed a link to reset your password. Detailed instructions for completing the online portion of the course can be found under the tab titled Course Instructions.
Once you have completed the 4-hour online portion and the 4-hour live portion of the course, return here to claim CME for the course. If you have any questions, please contact education@ASAM.org.
This project is supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) under grant number T0BHP28587 Medication-Assisted Treatment in Opioid Use Disorders. This information or content and conclusions should not be construed as the official position or policy of, nor should any endorsements be inferred by HRSA, HHS, or the U.S. Government.
Overview of Legislation
Physicians
The Drug Abuse Treatment Act of 2000 (DATA 2000) specifies training is necessary for physicians to obtain a waiver to engage in office‐based treatment of opioid use disorders using drugs approved by the FDA on Schedules III, IV, and V. This course addresses those requirements using a curriculum approved by CSAT/SAMHSA and ASAM, who is one of the national organizations named in the DATA 2000 legislation as eligible to prepare and administer these courses.
Nurse Practitioners & Physician Assistants
On July 22, 2016, President Obama signed the Comprehensive Addiction and Recovery Act (CARA) into law. CARA authorizes qualified NPs and PAs to become waivered to prescribe buprenorphine in office-based settings for patients with Opioid Use Disorder (OUD) for a five-year period expiring in October 2021.
To qualify, NPs and PAs must:
- Be licensed under state law to prescribe schedule III, IV, or V medications for pain
- Complete not less than 24 hours of appropriate education through a qualified provider
- Through other training or experience, demonstrate the ability to treat and manage OUD
- If required by state law, be supervised or work in collaboration with a qualifying physician to prescribe medications for the treatment of OUD
HHS' announcement on November 16, 2016, enables NPs and PAs to immediately begin taking the 24 hours of required training. For the full HHS announcement, click here.
NPs and PAs can begin the training immediately by taking the 8-hour buprenorphine course ASAM currently offers or that other stakeholders offer (see below for more information). The remaining 16 hours will have to be completed with one training provider. ASAM is developing multiple 16-hour training course options and formats, including collaborations with:
- 24-Hour Buprenorphine Curriculum Collaborative with the American Association of Nurse Practitioners (AANP) and the American Academy of Physician Assistants (AAPA)
- Clinical Tools, Inc
- Provider's Clinical Support System for Medication-Assisted Treatment (PCSS-MAT)
CME Information and Disclosure Listing
Date of Release: July 2015
Approved Through: July 2018
The American Society of Addiction Medicine (ASAM) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The American Society of Addiction Medicine designates this enduring material for a maximum of 4 AMA PRA Category 1 Credits™. Physicians should claim only credit commensurate with the extent of their participation in the activity.
The American Society of Addiction Medicine designates this live activity for a maximum of 4 AMA PRA Category 1 Credits™. Physicians should claim only credit commensurate with the extent of their participation in the activity.
The combined online enduring material and live activity will provide the required 8 hours needed to obtain the waiver to prescribe buprenorphine in office-based treatment of opioid use disorders.
This course has been designated as an approved CME Activity by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Maintenance of Certification (MOC) Program can apply a maximum of 8 AMA PRA Category 1 Credit(s)™ to the CME requirement for Part II: Lifelong Learning and Self-Assessment.
In accordance with the disclosure policies of ASAM and the ACCME, the effort is made to ensure balance, independence, objectivity, and scientific rigor in all educational activities. These policies include resolving all conflicts of interest between the CME Committee, Planning Committee and faculty, and commercial interests that might otherwise compromise the goal and educational integrity of this activity. All CME Committee, Planning Committee and faculty participating in the activity have disclosed all relevant financial relationships with commercial interests. The CME Committee has reviewed these disclosures and determined that the planning committee and faculty relationships are not inappropriate in the content of their respective presentations and are not inconsistent with the educational goals and integrity of the activity.
ASAM CME Committee
Name | Nature of Relevant Financial Relationship | ||
Commercial Interest | What was received? | For what role? | |
| Catherine Friedman, MD, FAPA, FASAM, Chair | None | ||
Adam J. Gordon, MD, MPH, FACP, DFASAM | None | ||
Edwin A. Salsitz, MD, DFASAM | None | ||
Herbert Malinoff, MD, FACP, DFASAM | None | ||
Noel Ilogu, MD, MRCP, DFASAM | None | ||
John Tanner, DO, FASAM | Indivior BDSI | Honorarium Honorarium | Speaker Speaker and Consultant |
ASAM Buprenorphine Program Planning Committee
Name | Nature of Relevant Financial Relationship | ||
Commercial Interest | What was received? | For what role? | |
Dan Alford, MD, MPH | None | ||
Andrew J. Saxon, MD | UpToDate | Royalties | Section Editor, Drug Use Disorders |
Colleen LaBelle, BSN, RN-BC, CARN | None | ||
Edwin Salsitz, MD, FASAM | None | ||
Jeffrey D. Baxter, MD | None | ||
Kelley Saia, MD | None | ||
Sharon Levy, MD, MPH | None | ||
Paula J. Lum, MD, MPH | None | ||
ASAM Buprenorphine Course Faculty
Name | Nature of Relevant Financial Relationship | ||
Commercial Interest | What was received? | For what role? | |
Edwin Salsitz, MD, FASAM | None | ||
Andrew J. Saxon, MD | UpToDate | Royalties | Senior Editor, Drug Use Disorders |
Colleen LaBelle, BSN, RN-BC, CARN | None | ||
Dan A. Alford, MD, MPH | None | ||
Jeffrey D. Baxter, MD | None | ||
Kelley Saia, MD | None | ||
Sharon Levy, MD, MPH | None | ||
Paula J. Lum, MD, MPH | None | ||
Sarah Bagley, MD | ASAM Millennium Fellowship Award | Partial Salary Support | Awardee |
Alexander Y. Walley, MD, MSc | None | ||
ASAM CME Committee Reviewers
Name | Nature of Relevant Financial Relationship | |||
Commercial Interest | What was received? | For what role? | ||
Adam J. Gordon, MD, MPH, FACP, FASAM | None | |||
Herbert Malinoff, MD, FACP, FASAM | None | |||
Learners will be able to:
- Apply for a waiver to prescribe buprenorphine to their patients with opioid use disorders
- Identify and assess patients who are appropriate for treatment with medications
- Have specific knowledge concerning the use of medications to manage patients with addiction involving opioid use
- Discuss the psychiatric and medical co-morbidities associated with opioid addiction
- Locate the box on the right that says “Module 1" and click “View Web Content On-Demand"
- Locate the box on the right that says “Certificate code" and enter the code given upon completion of Module 1 Part 1
- Continue to Module 1 Part 2 and Module 1 Part 3
- Once you have completed the entire module, locate the box called “Module 1 Quiz" and choose “Take Quiz"
- After you have completed Module 1 Quiz, continue to modules 2 and 3
- You will be required to pass all 3 Module Quizzes with a grade of 70% or higher
- Upon completion of both the 4 online hours and 4 live hours of the course, you will be able to claim CME Credit through the ASAM e-Learning Center
- Physicians, Nurse Practitioners, and Physician Assistants who wish to obtain a waiver to prescribe buprenorphine in office based treatment of opioid use disorders.
- Clinicians and health care team members working with physicians who prescribe buprenorphine in office based treatment of opioid use disorders.
The ASAM Treatment of Opioid Use Disorder Course has been made available in part by an unrestricted educational grant from Indivior Inc.
This project is supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) under grant number T0BHP28587 Medication-Assisted Treatment in Opioid Use Disorders. This information or content and conclusions should not be construed as the official position or policy of, nor should any endorsements be inferred by HRSA, HHS, or the U.S. Government.
Daniel P. Alford
MD, MPH, FACP, DFASAM
Daniel Alford, MD, MPH, FACP, DFASAM is a Professor of Medicine and Associate Dean of Continuing Medical Education at Boston University School of Medicine (BUSM). He is on staff in the Section of General Internal Medicine and Director of the Clinical Addiction Research and Education (CARE) Unit at Boston Medical Center. He is the Medical Director of the CDC-funded Boston Sustainable Models for unhealthy Alcohol use ReducTion (B SMART) and the HRSA funded SBIRT And FASD Education, Support and Treatment (SAFEST) Choice programs.
No relevant financial disclosures
Edwin A. Salsitz
MD, DFASAM
Dr. Edwin Salsitz has been an attending physician at Mt. Sinai Beth Israel, Division of Chemical Dependency, in New York City since 1983, and is an Associate Professor of Medicine at the Icahn School of Medicine at Mount Sinai. He is the principal investigator of the Methadone Medical Maintenance (office-based methadone maintenance) research project. Dr. Salsitz is certified by the American Board of Addiction Medicine (ABAM) and the Board of Internal Medicine and Pulmonary Disease.
No relevant financial disclosures
Sarah Bagley
MD
Sarah Bagley, MD, is an attending in the Departments of Medicine and Pediatrics at Boston Medical Center. Sarah completed a Combined Residency in Internal Medicine and Pediatrics at Brown and then an Addiction Medicine Fellowship at Boston University. Her clinical and research interest are related to the impact of substance use on families and in the treatment of adolescents with substance use disorders.
Jeffrey Baxter
MD
Jeff Baxter, MD, is an Associate Professor of Family Medicine and Community Health at the University of Massachusetts Medical School. Dr. Baxter completed a fellowship in Addiction Medicine at the Boston VA Medical Center, and is board certified in Family Medicine and Addiction Medicine. He currently serves as the Chief Medical Officer for Spectrum Health Systems Addiction Treatment Services, overseeing inpatient, outpatient and residential divisions.
Colleen LaBelle
BSN, RN-BC, CARN
Colleen LaBelle has certifications in addiction nursing and HIV with over 20 years of clinical experience in HIV and addiction, and co-authored a publication in the Journal of General Internal Medicine, “Treating Homeless Opioid Dependent Patients with Buprenorphine in an Office-based Setting." She was instrumental in the start up of the OBOT Program in the BMC Primary Care Clinic, which manages over 450 active patients with buprenorphine. This program provides buprenorphine treatment for patients in primary care, homeless, HIV, Family Medicine, OB, and support to the affiliated community health centers. She is the program director of the STATE OBOT B (State Technical Assistance, Treatment Expansion of Buprenorphine) working with 14 community health centers implementing a nurse care manager model for the expansion of buprenorphine. Since 2003, Ms. LaBelle has served as Faculty for the buprenorphine certification course of the American Society of Addiction Medicine. She frequently gives presentations on buprenorphine and provides consultation and technical assistance on- and offsite and by telephone. She oversees the MDPH buprenorphine list-serve and provides liaison for MDPH supported buprenorphine training, education and start-up in Massachusetts. She speaks on a local and national level, and has been a part of the SAMHSA Summit on Buprenorphine. Ms. LaBelle has served as a member of the Scientific Study (Study Section) Review Committee for the National Institute on Drug Abuse. Since 2004, she has served on the National Advisory Committee on Buprenorphine for the Health Resources and Services Administration and participated in professional editing of TAP 30 Technical Assistance Publication for Nurses with SAMHSA, 2009. Co-author : Five Year Experience with Collaborative Care of Opioid Addicted Patients using Buprenorphine in Primary Care, published Archives of Internal Medicine. In May 2011 she was the recipient of Individual Leadership Award, for Innovation In Health Care from MA Bureau of Substance Abuse Services as well as a NIATX award recipient 2011 Innovations in Behavioral Health Services award for Process Improvements. She is a board member of the Addiction Nurses Certification Board, and recently started a MA Chapter for addiction nurses.
Dr. Sharon Levy, MD, MPH
Director, Adolescent Substance Use and Addiction Program, Boston Children's Hospital
Sharon Levy, MD, MPH is a board certified Developmental-Behavioral Pediatrician and an Associate Professor of Pediatrics at Harvard Medical School. She is the Director of the Adolescent Substance use and Addiction Program (ASAP) in the Division of Developmental Medicine at Boston Children's Hospital. She has evaluated and treated thousands of adolescents with substance use disorders, and has taught national curricula and published extensively on the outpatient management of substance use disorders in adolescents, including screening and brief advice in primary care, the use of drug testing and the outpatient management of opioid dependent adolescents.
Paula Lum
MD, MPH, FASAM
Dr. Lum is a general internist and primary care physician, and Professor of Medicine in the HIV/AIDS Division in the University of California, San Francisco's Department of Medicine at San Francisco General Hospital. She is certified by the American Boards of Internal Medicine and Addiction Medicine.
Kelley Saia
MD
Kelley Saia, MD, is an attending obstetrician in the Department of Obstetrics and Gynecology at Boston Medical Center and an Assistant Professor of Obstetrics and Gynecology at Boston University School of Medicine.Dr. Saia received her medical degree from the University of Vermont, College of Medicine and completed her residency in obstetrics and gynecology at Boston Medical Center.
In addition to caring for women with general obstetrics and gynecologic issues, she is the director of Project RESPECT, Substance Use Disorder Treatment in pregnancy at Boston Medical Center. Project RESPECT has been caring for pregnant women with substance use disorder for over 30 years and Dr. Saia, established the first obstetric buprenorphine clinic in the greater Boston area in 2006. RESPECT cares for over 125 mother-baby pairs per year with a multidisciplinary team consisting of obstetricians, addiction medicine specialist, pediatrics, psychiatry, social work, lactation consultants and nursing. Dr. Saia is actively engaged in patient care QI, clinical and scientific research, community outreach and medical training.
Andrew Saxon
MD, FASAM
Andrew J. Saxon, M.D. Professor, Department of Psychiatry and Behavioral Sciences, University of Washington Director, Center of Excellence in Substance Abuse Treatment and Education, VA Puget Sound Health Care System Director, Addiction Psychiatry Residency Program, University of Washington Preceding his entry into psychiatry, Dr. Saxon completed an internal medicine internship and worked for 4 years as an emergency room physician. Subsequent to his general psychiatry residency at the University of Washington, Dr. Saxon has more than a quarter century of experience as a clinical and research addiction psychiatrist. Dr. Saxon is board certified with added qualifications in addiction psychiatry by the American Board of Psychiatry and Neurology. Dr. Saxon sits on the editorial boards of the journals, Drug and Alcohol Dependence and General Hospital Psychiatry. Dr. Saxon's current research work is supported by the VA, the Department of Defense, and the National Institute on Drug Abuse and involves pharmacotherapies and psychotherapies for alcohol, cocaine, tobacco, and opioid use disorders as well work in co-occurrence of substance use disorders and posttraumatic stress disorder and on reducing homelessness.
Alexander Y. Walley
MD, MSc, FASAM
Alexander Y. Walley, M.D., M.Sc., is an Associate Professor of Medicine at Boston University School of Medicine, a general internist and addiction medicine specialist at Boston Medical Center. He is the director of the Addiction Medicine Fellowship program and founded the Inpatient Addiction Consult Service at Boston Medical Center. He does clinical and research-related work on the medical complications of substance use, specifically HIV and overdose. He provides primary care and office-based buprenorphine treatment for HIV patients and methadone maintenance treatment. He is the medical director for the Massachusetts Department of Public Health’s Opioid Overdose Prevention Pilot Program.
No relevant financial disclosures.
Apply
- Fill out the Waiver Notification Form on SAMHSA’s website.
- Submit copies of your training certificate(s) to SAMHSA by email: infobuprenorphine@samhsa.hhs.gov or fax: 301.576.5237.
SAMHSA reviews waiver applications within 45 business days of receipt. If approved, you will receive a letter via email that confirms your waiver and includes your prescribing identification number.
Waiver applications are forwarded to the DEA. DEA regulations require your prescribing identification number to be included on all buprenorphine prescriptions for opioid dependency treatment, along with your regular DEA number.
If you have not received confirmation of receipt of your application, or if it has been more than 45 business days since submitting it, contact CSAT by email: infobuprenorphine@samhsa.hhs.gov or call 866.287.2728.
Please ensure that your state regulations allow you to prescribe buprenorphine and other medications to treat OUD before you apply for the waiver. Some states may have overriding state legislation that will prevent NPs and PAs from prescribing these medications even if Federal law allows it.
Apply
- Fill out the Waiver Notification Form on SAMHSA’s website.
- Submit copies of your training certificate(s) to SAMHSA by email: infobuprenorphine@samhsa.hhs.gov or fax: 301.576.5237.
SAMHSA reviews waiver applications within 45 business days of receipt. If approved, you will receive a letter via email that confirms your waiver and includes your prescribing identification number.
Waiver applications are forwarded to the DEA. DEA regulations require your prescribing identification number to be included on all buprenorphine prescriptions for opioid dependency treatment, along with your regular DEA number.
If you have not received confirmation of receipt of your application, or if it has been more than 45 business days since submitting it, contact CSAT by email: infobuprenorphine@samhsa.hhs.gov or call 866.287.2728.
Qualify
To qualify for a waiver to treat patients with Opioid Use Disorder, NPs and PAs must:
- Be licensed under state law to prescribe schedule III, IV, or V medications for pain
- Complete no less than 24 hours of appropriate education through a qualified provider
- Through other training or experience, demonstrate the ability to treat and manage OUD
- If required by state law, supervision or working in collaboration with a qualifying physician to prescribe medications for the treatment of OUD may be required.
Key:
Complete
Next
Failed
Available
Locked